Radio and PodcastLive Radio & PodcastsScience & Medicine
Colorectal Cancer: KRAS-Driven Selection Of Molecular Therapy Could Save Millions: Bevacizumab, Cetuximab, Panitumomab, or Combinations?
11th Annual Palm Beach Cancer Symposium (April 3-4, 2009 Hollywood, Florida)—Peter Goodwin interviews John Macdonald, Chief Medical Officer of Aptium Oncology in Los Angeles about his data on the relevance of KRAS tumor...
Related Episodes
Continue listening to more episodes from Oncology Times Broadcast News.
Longer Follow-up Reveals: Aspirin Prevents Cancer in Lynch Syndrome
Sep 28, 2009 - 00:07:19
For Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends Survival
Sep 28, 2009 - 00:06:03
Bevacizumab Did Not Improve Disease-Free Survival In Adjuvant Therapy For Early Colon Cancer
Sep 28, 2009 - 00:09:05
"Promising Activity" Of Cetuximab In Patients With Advanced Biliary Cancer
Sep 28, 2009 - 00:02:18